FUSED pyrimidines Compounds, inhibitors of p97 Complex； Pharmaceutical Composition and a method of decreasing the activity of valosin containing protein or degradation of a substrate to the Proteasome System.
Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.<；p>；COMPUESTOS DERIVADOS DE PIRIMIDINAS FUSIONADAS, INHIBIDORES DEL COMPLEJO P97； COMPOSICIONES FARMACOLÓ；GICAS Y SUS USOS； Ú；TILES EN EL TRATAMIENTO DE AFECCIONES RELACIONADAS A YUNA DISMINUCIÓ；N DE LA ACTIVIDAD DE PROTEÍ；NA QUE CONTIENE VALOSIN O PARA REDUCIR LA DEGRADACIÓ；N DE UN SUSTRATO DEL SISTEMA PROTEOSOMA.<；/p>；
